OverviewSuggest Edit

NanoString Technologies is a provider of life science tools for translational research and molecular diagnostics. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system; nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. It also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and pan cancer and 360 gene expression, CAR-T characterization, neuropathology and neuro-inflammation gene expression, autoimmune disease gene expression, miRNA expression, human organ transplant, human and mouse metabolic pathway, and human and mouse fibrosis panels.
TypePublic
Founded2003
HQSeattle, WA, US
Websitenanostring.com
Employee Ratings3.9
Overall CultureD-

Latest Updates

Employees (est.) (Dec 2019)551(+16%)
Job Openings62
Revenue (FY, 2020)$117.3 M(-6%)
Share Price (Sept 2021)$56
Cybersecurity ratingCMore

Key People/Management at NanoString Technologies

Brad Gray

Brad Gray

President and Chief Executive Officer
J. Chad Brown

J. Chad Brown

Senior Vice President, Sales and Marketing
Kathy Surace-Smith

Kathy Surace-Smith

Vice President, General Counsel and Corporate Secretary
Thomas Bailey

Thomas Bailey

Chief Financial Officer
Joseph M. Beechem

Joseph M. Beechem

Chief Scientific Officer & Senior Vice President, Research & Development
Janet George

Janet George

Director
Show more

NanoString Technologies Office Locations

NanoString Technologies has an office in Seattle
Seattle, WA, US (HQ)
530 Fairview Ave N #2000
Show all (1)

NanoString Technologies Financials and Metrics

NanoString Technologies Revenue

Embed Graph
View revenue for all periods
NanoString Technologies's revenue was reported to be $117.32 m in FY, 2020
USD

Revenue (Q1, 2021)

31.6m

Gross profit (Q1, 2021)

16.0m

Gross profit margin (Q1, 2021), %

50.6%

Net income (Q1, 2021)

(27.7m)

EBIT (Q1, 2021)

(25.9m)

Market capitalization (14-Sept-2021)

2.5b

Closing stock price (14-Sept-2021)

56.0

Cash (31-Mar-2021)

396.5m

EV

2.4b
NanoString Technologies's current market capitalization is $2.5 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

114.9m106.7m125.6m117.3m

Revenue growth, %

(7%)18%

Cost of goods sold

31.9m36.3m44.0m52.4m

Gross profit

83.0m70.4m81.5m64.9m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

18.1m34.6m27.0m23.1m25.0m28.6m27.7m30.3m30.6m26.6m21.1m31.6m

Cost of goods sold

7.2m8.2m7.3m7.7m8.6m9.3m8.7m9.6m10.9m11.0m15.6m

Gross profit

10.9m26.4m19.7m15.4m16.4m19.3m19.0m20.7m19.7m15.6m16.0m

Gross profit Margin, %

60%76%73%67%66%68%69%68%64%59%51%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

26.1m24.4m29.0m411.8m

Accounts Receivable

19.6m17.3m27.2m31.1m

Prepaid Expenses

4.7m7.3m8.8m4.2m

Inventories

20.1m13.2m19.8m23.0m
Quarterly
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(43.6m)(77.4m)(40.7m)(110.1m)

Depreciation and Amortization

3.4m4.1m4.9m5.7m

Inventories

(8.7m)5.3m(8.5m)(4.9m)

Accounts Payable

(110.0k)4.6m(599.0k)(3.2m)
USDQ1, 2017

Debt/Equity

-15.6 x

Debt/Assets

0.4 x

Financial Leverage

-34.8 x
Show all financial metrics

NanoString Technologies Operating Metrics

FY, 2017FY, 2018FY, 2019

Product Platforms

112

Facilities Leased

578

Patent Applications (US)

403627

Patents and Patent Applications

255266290
Show all operating metrics

NanoString Technologies Acquisitions / Subsidiaries

Company NameDateDeal Size
NanoString Technologies Asia Pacific Limited
NanoString Technologies (Bejing) Co. Ltd.
NanoString Technologies Europe Limited
NanoString Technologies Germany GmbH
NanoString Technologies International
NanoString Technologies SAS
NanoString Technologies Singapore Pte Limited
NanoString Technologies Spain, S.L.

NanoString Technologies Revenue Breakdown

Embed Graph

NanoString Technologies revenue breakdown by business segment: 24.7% from Instruments, 41.1% from Consumables, 7.5% from In Vitro Diagnostic Kits, 9.3% from Service and 17.4% from Collaboration

NanoString Technologies revenue breakdown by geographic segment: 68.6% from Americas, 24.1% from Europe & Middle East and 7.3% from Asia Pacific

NanoString Technologies Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

NanoString Technologies Online and Social Media Presence

Embed Graph

NanoString Technologies Company Culture

  • Overall Culture

    D-

    56/100

  • CEO Rating

    C+

    68/100

  • Compensation

    C+

    68/100

Learn more on Comparably

NanoString Technologies News and Updates

Worldwide Industry for Spatial Genomics and Transcriptomics to 2030 - Players Include NanoString Technologies, S2 Genomics & Flagship Biosciences Among Others

Dublin, Dec. 08, 2020 (GLOBE NEWSWIRE) -- The "Global Spatial Genomics and Transcriptomics Market: Focus on Product Type, Sample Type, Workflow, Application, End User, Region and Competitive Landscape - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

NanoString Technologies Announces Pricing of Public Offering of 4,500,000 Shares of Common Stock

SEATTLE, March 19, 2019 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price …

NanoString Technologies Announces Commencement of Public Offering of Common Stock

SEATTLE, March 18, 2019 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced an underwritten public offering of 4,500,000 shares of its common stock pursuant to its shelf regi…

NanoString Technologies Provides Preliminary Operational and Financial Results for Fourth Quarter and Fiscal Year 2018

— FY18 Product and Service Revenue of $83.5 million, Exceeding High-End of Guidance —— Generated Pre-Orders for More Than 30 GeoMx™ Digital Spatial Profilers —

NanoString Technologies Blogs

A Lab of Young Brainiacs Widens the Horizons in the Fight Against Neurological Diseases. Q&A with the Liddelow Lab.

The Liddelow Lab is part of the Neuroscience Institute at NYU Langone. The lab’s research focus is astrocytes and their... The post A Lab of Young Brainiacs Widens the Horizons in the Fight Against Neurological Diseases. Q&A with the Liddelow Lab. appeared first on NanoString.

Congratulations! Sarah Warren, PSBJ 40 Under 40 Honoree. Read Her Story.

The 40 Under 40 program, now in its 23rd year, includes professionals from life sciences, health care, aerospace, tech, food... The post Congratulations! Sarah Warren, PSBJ 40 Under 40 Honoree. Read Her Story. appeared first on NanoString.

The Partnership between NanoString and ROSALIND. The Experience of a Stem Cell Genomics and Microscopy Core in Sunny California.

In October 2020, NanoString® Technologies and ROSALIND announced a partnership to grant global access to the ROSALIND® Bioinformatics Platform for... The post The Partnership between NanoString and ROSALIND. The Experience of a Stem Cell Genomics and Microscopy Core in Sunny California. appeared fir…

Next Frontier in Cellular Therapy: A Q&A on Characterizing CAR-T Cells on a Grand Scale

In early June 2021, NanoString and the Parker Institute for Cancer Immunotherapy (PICI) announced a multi-center collaboration to characterize 800... The post Next Frontier in Cellular Therapy: A Q&A on Characterizing CAR-T Cells on a Grand Scale appeared first on NanoString.

What is Regenerative Medicine?

Regeneration or tissue renewal is an inherent characteristic of several mammalian tissues, such as epithelia and blood cells. In these... The post What is Regenerative Medicine? appeared first on NanoString.

CRO Spotlight: Invest in Today for a Better Tomorrow. A Chat with Oncocyte™ on Its Vision for a Disease-Free Future.

Oncocyte™ is a molecular diagnostic company located in Irvine, CA. It provides services aimed to accelerate and optimize the diagnosis... The post CRO Spotlight: Invest in Today for a Better Tomorrow. A Chat with Oncocyte™ on Its Vision for a Disease-Free Future. appeared first on NanoString.
Show more

NanoString Technologies Frequently Asked Questions

  • When was NanoString Technologies founded?

    NanoString Technologies was founded in 2003.

  • Who are NanoString Technologies key executives?

    NanoString Technologies's key executives are Brad Gray, J. Chad Brown and Kathy Surace-Smith.

  • How many employees does NanoString Technologies have?

    NanoString Technologies has 551 employees.

  • What is NanoString Technologies revenue?

    Latest NanoString Technologies annual revenue is $117.3 m.

  • What is NanoString Technologies revenue per employee?

    Latest NanoString Technologies revenue per employee is $212.9 k.

  • Who are NanoString Technologies competitors?

    Competitors of NanoString Technologies include Personalis, EKF Diagnostics and Klox Technologies.

  • Where is NanoString Technologies headquarters?

    NanoString Technologies headquarters is located at 530 Fairview Ave N #2000, Seattle.

  • Where are NanoString Technologies offices?

    NanoString Technologies has an office in Seattle.

  • How many offices does NanoString Technologies have?

    NanoString Technologies has 1 office.